Evidence map›Paper›PMID 26142736›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015

Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.

Junli Ma, Yan Zhang, Hong Shen, Linda Kapesa, Wenqiang Liu, Mengsi Zeng, Shan Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.International journal of environmental research and public health · 2016
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Junli MaDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yan ZhangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Hong ShenInstitute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Linda KapesaDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Wenqiang LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Mengsi ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. zengshan2000@yeah.net.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mismatch repair (MMR) gene is closely related to the pathogenesis of colon cancer. This study aimed to evaluate the association between MMR status and efficacy of irinotecan-based chemotherapy. As a target of 5-FU, thymidylate synthase (TS) expression level might be influenced by irinotecan. Understanding whether this influence of TS is related with MMR status is helpful to the further exploration of the mechanism of irinotecan sensitivity in metastatic colon cancer with different MMR status. One hundred eighty-four patients with metastatic colon cancer receiving irinotecan-based chemotherapy for the first-line treatment were included. Correlations between MMR and clinicopathological characteristics and prognosis were determined. Two pairs of colon cancer cell lines (HCT-116-hMLH1(Vector) (deficient MMR, dMMR) versus HCT-116-hMLH1(+) (proficient MMR, pMMR); SW480-shRNA-hMLH1 (dMMR) versus SW480-shRNA-Control (pMMR)) were established by regulating MMR status. Sensitivity of these cell lines to irinotecan was determined by MTT assay. Regulation of TS by irinotecan was evaluated by western blotting and quantitative real-time PCR assay. dMMR accounted for 18.5 % and was related with proximal colon cancer (p = 0.005), poorly differentiated tumors (p = 0.018) and favorable efficacy with a higher disease control rate (DCR), a longer progression-free survival (PFS) and a trend of longer overall survival (OS). dMMR colon cancer cells were more sensitive to irinotecan. TS expression level was reduced more in dMMR cells after irinotecan treatment (p < 0.05). Our study favors an increased sensitivity of irinotecan in colon cancer with dMMR status. MMR status may be a predictive biomarker of response to irinotecan-based chemotherapy in metastatic colon cancer.

Indexed as

Adaptor Proteins, Signal TransducingAgedCamptothecinColonic NeoplasmsDisease-Free SurvivalDNA Mismatch RepairFemaleFluorouracilGene Expression Regulation, NeoplasticHCT116 CellsHumansIrinotecanMaleMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinAdaptor Proteins, Signal TransducingCamptothecinFluorouracilIrinotecanMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsThymidylate Synthase5-FluorouracilColon cancerIrinotecanMismatch repair geneThymidylate synthase

Identifiers

PMID26142736
OpenAlexW790771705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.